UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2019

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**0-26642**	**87-0494517**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Public Common Stock, $0.01 par value	MYGN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 Results of Operations and Financial Condition.

On August 13, 2019, Myriad Genetics, Inc. ("Myriad") announced its financial results for the three and twelve months ended June 30, 2019. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

ITEM 7.01 Regulation FD Disclosure.

On its earnings conference call for the three and twelve months ended June 30, 2019, Myriad also delivered a slide presentation, which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. [The slide presentation will also be available under the "Investors –Events & Presentations" section of Myriad's website at www.myriad.com.]

FORWARD-LOOKING STATEMENTS

Exhibits 99.1 and 99.2 contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, goals, strategy and financial and operational outlook. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this information unless required by law.

ITEM 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number	Description
99.1	Earnings release dated August 13, 2019 for the three and twelve months ended June 30, 2019.
99.2	Earnings call slide presentation dated August 13, 2019 for the three and twelve months ended June 30, 2019.

The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: August 13, 2019

By: /s/ R. Bryan Riggsbee
R. Bryan Riggsbee
Executive Vice President, Chief Financial Officer

Exhibit 99.1

News Release

Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com
Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

- **Total Fourth-Quarter Revenues of $215.4 Million**
- **Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41**

SALT LAKE CITY, Aug. 13, 2019 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal fourth-quarter and full-year 2019, provided an update on recent business highlights and provided fiscal year and first-quarter 2020 financial guidance.

"Fiscal year 2019 revenue increased 14 percent with earnings up 18 percent. Unfortunately, revenue in the fourth quarter was two percent below expectations largely due to lower reimbursement for our expanded carrier screening test,” said Mark C. Capone, president and CEO, Myriad Genetics. “Looking ahead to fiscal year 2020, with stabilized pricing, growing new product volumes and recent reimbursement advances with GeneSight®, we are highly optimistic about our ability to deliver an inflection in revenue and earnings as we transition through the fiscal year.”

Financial Highlights

ummarizes the financial results for the fiscal fourth-quarter and full year 2019:

Revenue

($ in millions)	Fiscal Fourth-Quarter 2019	2018	% Change	Fiscal Year 2019	2018	% Change
Molecular diagnostic testing revenue						
Hereditary Cancer	$ 119.0	119.1	(0%)	$ 479.7	471.4	2%
GeneSight®	29.8	34.0	(12%)	112.6	124.9	(10%)
Prenatal	25.0	—	NM	104.9	—	NM
Vectra®	12.2	15.1	(19%)	48.3	55.2	(13%)
Prolaris®	6.3	7.0	(10%)	25.5	21.5	19%
EndoPredict®	3.0	2.7	11%	10.4	8.8	18%
Other testing revenue	1.6	2.7	(41%)	8.0	8.6	(7%)
Total molecular diagnostic testing revenue	196.9	180.6	9%	789.4	690.4	14%
Pharmaceutical and clinical service revenue	18.5	13.3	39%	61.7	53.3	16%
Total Revenue	$ 215.4	$ 193.9	11%	$ 851.1	$ 743.7	14%

Income Statement

($ in millions)	Fiscal Fourth-Quarter 2019	2018	% Change	Fiscal Year 2019	2018	% Change
Total Revenue	$ 215.4	193.9	11%	$ 851.1	$ 743.7	14%
Gross Profit	164.8	148.2	11%	650.1	566.5	15%
Gross Margin	76.5%	76.4%		76.4%	76.2%	
Operating Expenses	170.4	130.4	31%	642.5	444.6	45%
Operating Income	(5.6)	17.8	NM	7.6	121.9	(94%)
Operating Margin	(2.6%)	9.2%		0.9%	16.4%	
Adjusted Operating Income	33.2	41.5	(20%)	145.2	138.2	5%
Adjusted Operating Margin	15.4%	21.4%		17.1%	18.6%	
Net Income	(4.2)	14.5	NM	4.6	133.3	(97%)
Diluted EPS	$ (0.06)	$ 0.20	NM	$ 0.06	$ 1.85	(97%)
Adjusted EPS	$ 0.41	$ 0.43	(5%)	$ 1.67	$ 1.42	18%

Recent Business Highlights

- **Hereditary Cancer**
  - Hereditary cancer revenue returned to year-over-year growth in fiscal year 2019 representing the first time hereditary cancer revenue has grown in the last five fiscal years.
  - Presented data at the American Society of Clinical Oncology annual meeting from the Women's Health Initiative study that evaluated mutation rates in 2,195 post-menopausal women with breast cancer. The study found that women with post-menopausal breast cancer had a high rate of inherited mutations in a range of cancer causing genes and this mutation rate did not diminish with age. This along with other studies have shown that

current hereditary breast cancer testing guidelines miss approximately 50 percent of mutation carriers.

GeneSight®

- Announced coverage decision from UnitedHealth, the largest commercial payer in the United States, covering GeneSight for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication.
- Announced coverage decision for GeneSight by Kroger® Prescription Plans. As part of the agreement, Kroger initiated an early access program at 500 Kroger pharmacies where GeneSight testing will be facilitated by the Kroger Health pharmacist.
- Presented data at the Clinical Pharmacogenomics Implementation Consortium annual meeting showing GeneSight had more than double the predictive power for drug blood levels compared to single gene pharmacogenomics tests.
- Completed a Medicare Coverage Advisory Committee meeting reviewing potential expansion of the GeneSight LCD to primary care physicians. During the meeting, Medicare's selected subject matter experts unanimously agreed that pharmacogenomics testing should be available to primary care physicians.

- **Prolaris®**
  - Published data from a large study of 1,062 men with newly diagnosed localized prostate cancer to evaluate the ability of the Prolaris test to predict risk of metastases. The study found that Prolaris was the strongest independent predictor of progression to metastatic disease, and men were approximately three times more likely to develop metastatic disease with each unit increase in the Prolaris test score (HR: 2.93; $p=1.8x10^{-11}$).

- **EndoPredict®**
  - Published data in the journal *Clinical Cancer Research* demonstrating that the EndoPredict test identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis.
  - Published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict test compared to other breast cancer assays. The study found that the EndoPredict test was more than twice as cost effective as Oncotype® DX.
- **Companion Diagnostics**
  - Announced that the BRACAnalysis CDx® companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with Lynparza®

(olaparib) in the Phase III POLO study. Patients in the study with a germline mutation had a clinically-meaningful and statistically-significant improvement in progression-free survival (PFS) of 7.4 months when treated with Lynparza compared to 3.8 months for placebo (HR 0.53; p=0.004).
    - Received approval from the Japanese Ministry of Health, Labour, and Welfare for Myriad's BRACAnalysis® Diagnostic System as a companion for Lynparza in women with ovarian cancer.
    - Announced that BRACAnalysis CDx effectively identified patients with castrate resistant, metastatic prostate cancer who benefitted from treatment with Lynparza in the PROfound study. Results from the study showed a statistically-significant and clinically-meaningful improvement in radiographic progression-free survival in patients who received Lynparza vs. enzalutamide or abiraterone and had deleterious mutations in the BRCA1/2 genes.
- **myPath® Melanoma**
    - Received a positive final local coverage decision from Noridian Healthcare Solutions for myPath Melanoma.
- **German Clinic Sale**
    - Announced planned sale of the Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the "Clinic"), which is expected to occur around the middle of fiscal year 2020.

Fiscal Year 2020 and Fiscal First-Quarter 2020 Financial Guidance

Below is a table summarizing Myriad's fiscal year 2020 and fiscal first-quarter 2020 financial guidance:

	Revenue	GAAP Diluted Earnings Per Share	Adjusted Earnings Per Share
Fiscal Year 2020	$865-875 million	$0.55-$0.65	$1.80-$1.90
Fiscal First-Quarter 2020	$200-$202 million	($0.02)-$0.00	$0.30-$0.32

Myriad's fiscal year 2020 and first-quarter 2020 adjusted earnings per share guidance excludes the impact of stock based compensation expense, non-cash amortization associated with acquisitions and certain non-recurring expenses. These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The company will provide further details on its business outlook during the conference call today and discuss the fiscal fourth-quarter financial results and fiscal year 2020 financial guidance.

Conference Call and Webcast

A conference call will be held today, Tuesday, August 13, 2019, at 4:30 p.m. EDT to discuss Myriad's financial results for the fiscal fourth-quarter, business developments and financial guidance. The dial-in number for domestic callers is 1-800-763-5615. International callers may dial 1-212-231-2936. All callers will be asked to reference reservation number 21927089. An archived replay of the call will be available for seven days by dialing (800) 633-8284 and entering the reservation number above. The conference call along with a slide presentation will also will be available through a live webcast at www.myriad.com.

About Myriad Genetics

Myriad Genetics, Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS (Unaudited)
(in millions, except per share amounts)

	Three months ended June 30,		Twelve months ended June 30,	
	2019	2018	2019	2018
Molecular diagnostic testing	$ 196.9	$ 180.6	$ 789.4	$ 690.4
Pharmaceutical and clinical services	18.5	13.3	61.7	53.3
Total revenue	215.4	193.9	851.1	743.7
Costs and expenses:				
Cost of molecular diagnostic testing	41.6	38.0	168.2	148.7
Cost of pharmaceutical and clinical services	9.0	7.7	32.8	28.5
Research and development expense	20.9	17.7	85.9	70.8
Change in the fair value of contingent consideration	(0.3)	0.2	1.1	(61.2)
Selling, general, and administrative expense	149.8	112.5	555.5	435.0
Total costs and expenses	221.0	176.1	843.5	621.8
Operating income	(5.6)	17.8	7.6	121.9
Other income (expense):				
Interest income	0.9	0.5	3.2	1.8
Interest expense	(3.2)	(1.1)	(12.0)	(3.2)
Other	0.2	0.8	1.2	(0.4)
Total other expense:	(2.1)	0.2	(7.6)	(1.8)
Income before income tax	(7.7)	18.0	—	120.1
Income tax provision	(3.4)	3.5	(4.4)	(13.0)
Net income	$ (4.3)	$ 14.5	$ 4.4	$ 133.1
Net loss attributable to non-controlling interest	(0.1)	—	(0.2)	(0.2)
Net income attributable to Myriad Genetics, Inc. stockholders	$ (4.2)	$ 14.5	$ 4.6	$ 133.3
Earnings per share:				
Basic	$ (0.06)	$ 0.21	$ 0.06	$ 1.92
Diluted	$ (0.06)	$ 0.20	$ 0.06	$ 1.85
Weighted average shares outstanding:				
Basic	73.4	70.1	73.5	69.4
Diluted	74.8	72.9	76.0	72.0

Consolidated Balance Sheets (Unaudited)

(in millions)

ASSETS	June 30, 2019	June 30, 2018
Current assets:		
Cash and cash equivalents	$ 93.2	$ 110.9
Marketable investment securities	43.7	69.7
Prepaid expenses	16.6	9.4
Inventory	31.4	34.3
Trade accounts receivable	133.9	99.5
Prepaid taxes	25.1	—
Other receivables	4.7	3.8
Total current assets	348.6	327.6
Property, plant and equipment, net	57.3	43.2
Long-term marketable investment securities	54.9	30.7
Intangibles, net	684.7	455.2
Goodwill	417.2	318.6
Total assets	$ 1,562.7	$ 1,175.3
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 33.3	$ 26.0
Accrued liabilities	78.9	68.3
Short-term contingent consideration	3.4	5.3
Deferred revenue	2.2	2.6
Total current liabilities	117.8	102.2
Unrecognized tax benefits	21.7	24.9
Other long-term liabilities	7.8	6.3
Contingent consideration	10.4	9.2
Long-term debt	233.5	9.3
Long-term deferred taxes	82.6	57.3
Total liabilities	473.8	209.2
Commitments and contingencies		
Stockholders’ equity:		
Common stock, 73.5 and 70.6 shares outstanding at June 30, 2019 and 2018 respectively	0.7	0.7
Additional paid-in capital	1,068.0	915.4
Accumulated other comprehensive loss	(5.4)	(4.1)
Retained earnings	25.6	54.1
Total Myriad Genetics, Inc. stockholders’ equity	1,088.9	966.1
Non-Controlling Interest	—	—
Total stockholders' equity	1,088.9	966.1
Total liabilities and stockholders’ equity	$ 1,562.7	$ 1,175.3

Consolidated Statement of Cash Flows (Unaudited)

(in millions)

	Twelve months ended June 30,	
	2019	**2018**
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Income attributable to Myriad Genetics, Inc. stockholders	$ 4.6	133.3
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	73.0	54.4
Non-cash interest expense	0.4	0.2
Gain on disposition of assets	(0.9)	(0.2)
Share-based compensation expense	33.5	27.1
Deferred income taxes	18.6	(23.5)
Unrecognized tax benefits	(5.5)	(0.3)
Change in fair value of contingent consideration	(1.4)	(60.9)
Payment of contingent consideration	(1.5)	(22.7)
Changes in assets and liabilities:		
Prepaid expenses	(3.2)	3.3
Trade accounts receivable	(18.2)	(9.1)
Other receivables	(0.7)	1.1
Inventory	8.0	7.9
Prepaid taxes	(25.1)	—
Accounts payable	1.1	4.0
Accrued liabilities	1.5	1.4
Deferred revenue	(0.5)	(0.1)
Net cash provided by operating activities	83.7	115.9
CASH FLOWS FROM INVESTING ACTIVITIES		
Capital expenditures	(8.6)	(8.4)
Acquisitions, net of cash acquired	(278.5)	—
Purchases of marketable investment securities	(78.5)	(80.9)
Proceeds from maturities and sales of marketable investment securities	79.2	77.7
Net cash used in investing activities	(286.4)	(11.6)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net proceeds from common stock issued under share-based compensation plans	8.7	36.9
Net proceeds from revolving credit facility	340.0	53.0
Repayment of revolving credit facility	(115.0)	(143.0)
Fees associated with refinancing of revolving credit facility	(1.4)	—
Payment of contingent consideration recorded in purchase accounting	—	(42.4)
Repurchase and retirement of common stock	(50.0)	—
Proceeds from non-controlling interest	—	0.5
Net cash provided by (used in) financing activities	182.3	(95.0)
Effect of foreign exchange rates on cash and cash equivalents	2.7	(0.8)
Net increase (decrease) in cash and cash equivalents	(17.7)	8.5
Cash and cash equivalents at beginning of the period	110.9	102.4
Cash and cash equivalents at end of the period	$ 93.2	$ 110.9

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company’s ability to deliver an inflection in revenue and earnings as it transitions through fiscal year 2020; the potential expansion of the GeneSight LCD to primary care physicians; the planned sale of the German Clinic and the expectation that the sale will occur around the middle of fiscal year 2020; the Company’s fiscal year 2020 and fiscal first-quarter 2020 financial guidance for revenue, GAAP diluted earnings per share, and adjusted earnings per share under the caption “Fiscal Year 2020 and Fiscal First-Quarter 2020 Financial Guidance”; and the Company’s five critical success factors of building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally, and improving profitability with Elevate 2020 under the caption “About Myriad Genetics.” These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of the Company’s existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to the Company’s ability to successfully transition from its existing product portfolio to its new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for the Company’s tests or the Company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the Company may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that the Company may not successfully develop new markets for its molecular diagnostic tests and pharmaceutical and clinical services, including the Company’s ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying the Company’s molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the Company’s laboratory testing facilities; risks related to public concern over the Company’s genetic testing in general or the Company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Company’s ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to the Company’s ability to successfully integrate and derive benefits from any technologies or businesses

that it licenses or acquires; risks related to the Company's projections about the potential market opportunity for the Company's products; the risk that the Company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the Company's tests; the risk of patent-infringement claims or challenges to the validity of the Company's patents; risks related to changes in intellectual property laws covering the Company's molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the Company may be unable to comply with financial operating covenants under the Company's credit or lending agreements; the risk that the Company will be unable to pay, when due, amounts due under the Company's credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Statement regarding use of non-GAAP financial measures

In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached schedules.

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets: Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights.
- Acquisition – integration related costs: Costs related to closing and integration of acquired companies
- Equity compensation – non-cash equity based compensation provided to Myriad employees
- Deferred Tax impact of non-GAAP adjustments: Changes in effective tax rate based upon ASU 2016-09 and the deferred tax impact of non-deductible acquisition costs
- Tax reform impact – The impact of tax reform legislation on deferred tax assets
- Potential future consideration related to acquisitions: Non-cash expenses related to valuation adjustments of earn-out and milestone payments tied to recent acquisitions
- Settlement of Hereditary Cancer Qui Tam Complaint – Expenses tied to the one-time settlement of the Qui Tam Complaint against Myriad around hereditary cancer billing
- Non-recurring legal expenses: One-time non-recurring legal settlements
- Elevate 2020 costs: Expenses tied to Elevate 2020 program

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Reconciliation of GAAP to Non-GAAP Financial Measures
for the Three and Twelve months ended March 31, 2019
(Unaudited data in millions, except per share amount)

	Three Months Ended		Twelve Months Ended	
	Jun 30, 2019	Jun 30, 2018	Jun 30, 2019	Jun 30, 2018
Revenue	$ 215.4	$ 193.9	$ 851.1	$ 743.7
GAAP Cost of molecular diagnostic testing	41.6	38.0	168.2	148.7
GAAP Cost of pharmaceutical and clinical services	9.0	7.7	32.8	28.5
Acquisition - Integration related costs	—	—	(0.2)	—
Equity Compensation	(0.2)	(0.1)	(0.7)	(0.9)
Elevate 2020 costs	(0.4)	(2.8)	(4.2)	(3.0)
Non-GAAP COGS	$ 50.0	$ 42.8	$ 195.9	$ 173.3
Non-GAAP Gross Margin	76.8%	77.9%	77.0%	76.7%
GAAP Research and Development	$ 20.9	$ 17.7	$ 85.9	$ 70.8
Acquisition - amortization of intangible assets	(0.1)	(0.1)	(0.3)	(0.3)
Acquisition - Integration related costs	(0.1)	—	(0.8)	(0.1)
Equity compensation	(1.4)	(1.3)	(5.6)	(4.3)
Elevate 2020 costs	—	(0.7)	(2.2)	(1.8)
Non-GAAP R&D	$ 19.3	$ 15.6	$ 77.0	$ 64.3
GAAP Contingent Consideration	$ (0.3)	$ 0.2	$ 1.1	$ (61.2)
Potential future consideration related to acquisitions	0.3	(0.2)	(1.1)	61.2
Non-GAAP Contingent Consideration	$ —	$ —	$ —	$ —
GAAP Selling, General and Administrative	$ 149.8	$ 112.5	$ 555.5	$ 435.0
Acquisition - amortization of intangible assets	(15.1)	(9.1)	(58.7)	(36.6)
Acquisition - Integration related costs	(2.8)	(0.6)	(20.8)	(0.9)
Equity compensation	(7.1)	(5.8)	(27.1)	(21.9)
Non-Recurring Legal Expenses	—	(0.5)	—	(0.5)
Elevate 2020 costs	(2.8)	(2.5)	(6.8)	(7.2)
Settlement of hereditary cancer Qui Tam complaint	(9.1)	—	(9.1)	—
Non-GAAP SG&A	$ 112.9	$ 94.0	$ 433.0	$ 367.9
GAAP Operating Income	$ (5.6)	$ 17.8	$ 7.6	$ 121.9
Acquisition - Integration related costs	2.9	0.6	21.8	1.0
Acquisition - amortization of intangible assets	15.2	9.2	59.0	36.9
Equity compensation	8.7	7.2	33.4	27.1
Non-Recurring Legal Expenses	—	0.5	—	0.5
Elevate 2020 costs	3.2	6.0	13.2	12.0
Potential future consideration related to acquisitions	(0.3)	0.2	1.1	(61.2)
Settlement of hereditary cancer Qui Tam complaint	9.1	—	9.1	—
Non-GAAP Operating Income	$ 33.2	$ 41.5	$ 145.2	$ 138.2
Non-GAAP Operating Margin	15%	21%	17%	19%
GAAP Net Income Attributable to Myriad Genetics, Inc. Stockholders	$ (4.2)	$ 14.5	$ 4.6	$ 133.3
Acquisition - Integration related costs	2.9	0.6	21.8	1.0
Acquisition - amortization of intangible assets	15.2	9.2	59.0	36.9
Equity compensation	8.7	7.2	33.4	27.1
Non-Recurring Legal Expenses	—	0.5	—	0.5
Elevate 2020 costs	3.2	6.0	13.2	12.0
Potential future consideration related to acquisitions	(0.3)	0.2	1.1	(61.2)
Settlement of hereditary cancer Qui Tam complaint	9.1	—	9.1	—
Tax reform impact	—	(1.8)	—	(34.4)
Deferred tax impact of non-GAAP adjustments	(0.6)	(0.1)	2.2	(0.4)
Tax effect associated with non-GAAP adjustments	(3.3)	(4.8)	(17.5)	(12.5)

Non-GAAP Net Income	$ 30.7	$ 31.5	$ 126.9	$ 102.3
GAAP Diluted EPS	$ (0.06)	$ 0.20	$ 0.06	$ 1.85
Non-GAAP Diluted EPS	$ 0.41	$ 0.43	$ 1.67	$ 1.42
Diluted shares outstanding	74.8	72.9	76.0	72.0

Free Cash Flow Reconciliation
(Unaudited data in millions)

	Three Months Ended		Twelve Months Ended	
	Jun 30, 2019	Jun 30, 2018	Jun 30, 2019	Jun 30, 2018
GAAP cash flow from operations	$ 31.5	$ 47.9	$ 83.7	$ 115.9
Capital expenditures	(1.4)	(1.8)	(8.6)	(8.4)
Free cash flow	$ 30.1	$ 46.1	$ 75.1	$ 107.5
Elevate 2020 costs	3.2	3.7	13.2	9.7
Acquisition - Integration related costs	2.9	0.6	21.8	—
Cash paid for contingent consideration in operating cash flows	—	1.9	1.5	22.7
Tax effect associated with non-GAAP adjustments	(1.7)	(1.7)	(10.2)	(9.1)
Non-GAAP Free cash flow	$ 34.5	$ 50.6	$ 101.4	$ 130.8

Reconciliation of GAAP to Non-GAAP for Fiscal Year 2020

The Company's future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from guidance set forth below. Some of the factors that could affect the Company's financial results are stated in the safe harbor statement of this press release. More information on potential factors that could affect the Company's financial results are included under the heading "Risk Factors" contained in Item 1A in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

	Fiscal Year 2020
Diluted net income per share	
GAAP diluted net income per share	$0.55 - $0.60
Stock Based Compensation Expense	0.30
Acquisition - amortization of intangible assets	0.80
Adjustments to GAAP financial measures	0.15
Non-GAAP diluted net income per share	**$1.80 - $1.90**

	Fiscal First-Quarter 2020
Diluted net income per share	
GAAP diluted net income per share	($0.02) - $0.00
Stock Based Compensation Expense	0.08
Acquisition - amortization of intangible assets	0.20
Adjustments to GAAP financial measures	0.04
Non-GAAP diluted net income per share	**$0.30 - $0.32**

Exhibit 99.2

Myriad Genetics Fiscal Fourth-Quarter 2019 Earnings Call

August 13, 2019

myriad®
WHEN DECISIONS MATTER

Forward Looking Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

	Fiscal Year 2020
GAAP diluted earnings per share	$0.55-$0.65
Stock based compensation expense	$0.30
Acquisition – amortization of intangible assets	$0.80
Adjustments to GAAP financial measures	$0.15
Non-GAAP diluted earnings per share	**$1.80-$1.90**
	Fiscal First-Quarter 2020
GAAP diluted earnings per share	($0.02)-$0.00
Stock based compensation expense	$0.08
Acquisition – amortization of intangible assets	$0.20
Adjustments to GAAP financial measures	$0.04
Non-GAAP diluted earnings per share	**$0.30-$0.32**

For additional information on GAAP to non-GAAP reconciliation see: https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/

Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A link to reconciliation of the GAAP to non-GAAP financial guidance is provided above.

myriad WHEN DECISIONS MATTER

Fiscal Year 2019 Highlights

FINANCIALS

- Revenue of $851 and adjusted EPS of $1.67 up 14% and 18% respectively

SOLID HEREDITARY CANCER FOUNDATION

- Hereditary cancer revenue grows for first time in five years
- New colon, pancreatic, breast & prostate guidelines add 160,000 patients per year
- ASBS guidelines recommend hereditary cancer testing for all breast cancer patients

DIVERSIFY WITH NEW PRODUCTS

- New product volume reaches 800,000 tests representing 75% of test volume
- GeneSight® volume increases 17% year-over-year
- Completed Counsyl integration
- Submitted PMA for myChoice® HRD in advanced ovarian cancer

myriad WHEN DECISIONS MATTER

Fiscal Year 2019 Highlights

EXPAND REIMBURSEMENT

- GUIDED study published; GeneSight dossier submitted to all payers
- UnitedHealth coverage decision for GeneSight
- Launched employer and PBM channel – signed Kroger® agreement
- Completed publication supporting expanded gene criteria in ECS
- Received favorable myPath® Melanoma LCD from Medicare

INCREASE INTERNATIONAL REVENUE

- New EndoPredict® reimbursement in UK, Italy and Greece
- Two new Japan CDx indications in metastatic breast cancer and ovarian cancer

ELEVATE 2020

- Organic gross margins increased >300 basis points
- Brought Counsyl® from $12M quarterly loss to profitability in 3 quarters

myriad WHEN DECISIONS MATTER

Financial Overview

Fiscal Fourth-Quarter Revenue By Product

(in millions)

Product	4Q19	3Q19	Seq. Growth
Hereditary Cancer	$119.0	$117.6	1%
GeneSight	$29.8	$29.6	1%
Prenatal Testing	$25.0	$30.6	(22%)
Vectra®	$12.2	$11.3	8%
Prolaris®	$6.3	$6.9	(9%)
EndoPredict	$3.0	$2.8	7%
Other	$1.6	$1.7	(6%)
Total Molecular Diagnostic Revenue	**$196.9**	**$200.5**	**(2%)**
Pharmaceutical & Clinical Services	$18.5	$16.1	15%
Total Revenue	**$215.4**	**$216.6**	**(1%)**

myriad WHEN DECISIONS MATTER

Fiscal Fourth-Quarter Financial Results

	GAAP Results			Adjusted Results		
	4Q19	4Q18	YoY Growth	4Q19	4Q18	YoY Growth
Total Revenue	**$215.4**	**$193.9**	**14%**	**$215.4**	**$193.9**	**14%**
Gross Profit	$164.8	$148.2	11%	$165.4	$151.1	9%
Gross Margin	76.5%	76.4%	+10 bps	76.8%	77.9%	-110 bps
Operating Income	($5.6)	$17.8	NM	$33.2	$41.5	(20%)
Operating Margin	(2.6%)	9.2%	-1180 bps	15.4%	21.4%	-600 bps
Net Income	($4.2)	$14.5	NM	$30.7	$31.5	(3%)
EPS	**($0.06)**	**$0.20**	**NM**	**$0.41**	**$0.43**	**(5%)**

myriad WHEN DECISIONS MATTER

FY20 and 1Q FY20 Financial Guidance

Metric	Fiscal Year 2020	1Q FY20
Revenue	$865-$875 million	$200-$202 million
GAAP Diluted EPS	$0.55-$0.65	($0.02)-$0.00
Adjusted EPS	$1.80-$1.90	$0.30-$0.32

Potential Upside Drivers to Financial Guidance

Product	1H20	2H20
myRisk Hereditary Cancer BRACAnalysis CDx	NCCN breast cancer guidelines U.S. CDx for pancreatic cancer Japan CDx for ovarian cancer	U.S. CDx for prostate cancer Japan hereditary cancer
genesight	Commercial payer coverage Employer/PBM coverage	Medicare LCD expansion Expand sales force
Foresight Prequel Prenatal Screen	ACOG guidelines for average risk	Updated ECS guidelines
myPath Melanoma	Medicare revenue	Increased coverage
myChoice HRD	U.S.CDx launch in ovarian cancer	
Vectra	Launch of RP risk prediction ACR guidelines	Launch of CVD risk prediction
Prolaris	Incremental reimbursement coverage	

Potential Market for GeneSight Psychotropic: $13B TAM

Based upon $2,000 average selling price assumption.

Key Clinical Evidence for GeneSight

Precision Medicine Analysis[1] (Patients Entering GUIDED on Medications With Any GDI)





Switching Analysis[2] (Patients Entering GUIDED on Medications With Significant GDI)



[1] Data on file

[2] Greden et al, Journal of Psychiatric Research, Jan. 2019, Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

Combinatorial Pharmacogenomics Superior to Single-GeneTesting



[1] Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients With Major Depressive Disorder; Poster presented at the 2019 Clinical Pharmacogenetics Implementation Consortium (**CPIC®**) Annual Meeting

UnitedHealthcare to Cover GeneSight

UnitedHealthcare®

UnitedHealthcare® Commercial
Medical Policy

PHARMACOGENETIC TESTING

Policy Number: 2019T0587E **Effective Date**: October 1, 2019

Instructions for Use

Table of Contents **Page**

Related Commercial Policies
- Cardiovascular Disease Risk Tests
- Chemosensitivity and Chemoresistance Assays in Cancer

Community Plan Policy
- Pharmacogenetic Testing

Medicare Advantage Coverage Summaries
- Genetic Testing
- Laboratory Tests and Services

COVERAGE RATIONALE

The use of pharmacogenetic Multi-Gene Panels to guide therapy decisions is proven and medically necessary for antidepressants and antipsychotics medication when ALL of the following criteria are met:
- The individual has a diagnosis of major depressive disorder or anxiety; **and**
- The individual has failed at least one prior medication to treat their condition; **and**
- The Multi-Gene Panel has no more than 15 relevant genes (refer to Table 1).

myriad WHEN DECISIONS MATTER

Status of Coverage Decisions on GeneSight

Payer/Tech Assessor	Coverage	Comments
Medicare	Yes	Submitted dossier for coverage expansion to primary care
CareFirst	Yes	All providers
Kroger	Yes	Pharmacy intervention
Fortune 50 Company	Yes	Coverage in 1Q20
UnitedHealthcare®	Yes	All providers
Evidence Street®	No	Minimal evidence gaps – resubmitting for priority review
Anthem®	No	Re-engaged following Kroger announcement
eviCore®	No	Addressing errors in technical assessment; re-engaging with precision medicine analysis

Guideline Expansions in Hereditary Cancer

Cancer Type	Expansion in Guidelines	Number of New Patients Qualifying for Testing	CDx Indication?
Prostate Cancer	All metastatic prostate cancer; all patients with a family history of breast cancer regardless of Gleason score	+40,000	Expected in FY20
Pancreatic Cancer	All pancreatic cancer	+40,000	Expected in FY20
Colorectal Cancer	Lowered risk threshold to meet criteria for testing	+41,000	No
Metastatic Breast Cancer	All metastatic breast cancer	+40,000	Yes
Breast Cancer	All breast cancer patients	+180,000	Expected in FY21

myriad WHEN DECISIONS MATTER

Positive Leading Indicators for Prenatal Market Growth



How we win:



Expanding Clinical Utility for Vectra



One test, three clinical answers which impact patient care

Myriad: The Investment Thesis

Precision medicine is entering a hyper-growth phase

Molecular diagnostics are the keystone to improving patient outcomes and eliminating wasted spend

Myriad is the global leader in this market

Near-term catalysts can triple earnings

Compelling investment opportunity